Related Experiment Videos
Kawasaki disease
1University of Southern California School of Medicine, Los Angeles 90027-6016, USA.
Insights
Kawasaki disease presents atypically in 10% of cases, potentially delaying treatment and increasing coronary artery aneurysm risk. Intravenous gamma globulin is standard, but safety concerns and new diagnostics require evaluation.
Area of Science:
- Pediatrics
- Cardiology
- Immunology
Background:
- Kawasaki disease incidence is significantly higher in Japan than in the US.
- Atypical presentations occur in approximately 10% of patients, complicating diagnosis.
- Coronary artery complications are a primary concern in Kawasaki disease management.
Purpose of the Study:
- To highlight diagnostic challenges in atypical Kawasaki disease cases.
- To discuss current treatment mainstays and their associated risks.
- To emphasize the need for evaluating new diagnostic and therapeutic approaches.
Main Methods:
- Review of existing literature on Kawasaki disease epidemiology and clinical presentations.
- Analysis of diagnostic criteria and their impact on treatment initiation.
- Examination of current therapeutic strategies, including intravenous gamma globulin and surgical options.
Main Results:
- Atypical presentations often lead to delayed or missed diagnosis, increasing the risk of coronary artery aneurysms.
- Intravenous gamma globulin is the primary acute treatment, but safety concerns regarding viral transmission exist.
- Newer diagnostic modalities show promise but require further validation for long-term follow-up.
Conclusions:
- Early and accurate diagnosis is crucial, especially in atypical Kawasaki disease cases, to prevent coronary artery complications.
- While intravenous gamma globulin remains essential, ongoing safety monitoring and exploration of alternatives are necessary.
- Careful evaluation of emerging diagnostic tools and cautious application of surgical interventions are recommended for optimal patient outcomes.
Abstract:
Incidence of Kawasaki disease in Japan is 10 times higher than in the United States. Approximately 10% of patients have atypical clinical presentations. Because echocardiographic or angiographic evidence of coronary artery complications is needed for diagnosis, such atypical cases often result in either delay or omission of intravenous gamma globulin therapy and higher incidence of coronary artery aneurysms than those patients with classical presentations. Despite ongoing research, no universally accepted etiologic theory exists today. Intravenous gamma globulin remains the mainstay of the acute phase treatment of Kawasaki disease. However, reported transmission of hepatitis C virus via a brand of intravenous gamm globulin leaves us with a lingering concern about the safety of this treatment. In terms of long-term follow-up, emergencence of a number of newer diagnostic modalities is promising and warrants careful evaluation. Surgical therapy for coronary artery disease needs to be approached cautiously.